Live Breaking News & Updates on Halozyme Therapeutic

Stay updated with breaking news from Halozyme therapeutic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Zacks Research Comments on Halozyme Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Investment analysts at Zacks Research lifted their FY2026 earnings per share estimates for Halozyme Therapeutics in a research report issued to clients and investors on Monday, April 22nd. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings of $5.16 per share for […] ....

United States , Michaelj Labarre , Commonwealth Equity Services , Vontobel Holding Ltd , Goldman Sachs Group , Halozyme Therapeutics Company Profile , Linden Thomas Advisory Services , Exchange Traded Concepts , Zacks Research , Halozyme Therapeutics Inc , Halozyme Therapeutics , Free Report , Halozyme Therapeutic , Get Free Report , Traded Concepts , Thomas Advisory Services , Equity Services , Halozyme Therapeutics Daily , Nasdaq Halo , Earnings Estimates ,

Research Analysts Offer Predictions for Halozyme Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Research analysts at Leerink Partnrs cut their Q1 2024 earnings estimates for shares of Halozyme Therapeutics in a note issued to investors on Wednesday, April 3rd. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings of $0.58 per share for the quarter, […] ....

United States , Michaelj Labarre , Leerink Partnrs , Hsbc Holdings , Goldman Sachs Group , Campbell Co Investment Adviser , Morgan Stanley , Halozyme Therapeutics Inc , Allspring Global Investments Holdings , Securities Exchange Commission , Halozyme Therapeutics , Free Report , Halozyme Therapeutic , Get Free Report , Exchange Commission , Global Investments Holdings , Investment Counsel , Boston Partners , Halozyme Therapeutics Daily , Nasdaq Halo , Earnings Estimates ,

Is Now The Time To Put Halozyme Therapeutics (NASDAQ:HALO) On Your Watchlist?

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story. ....

Halozyme Therapeutic , Halozyme Therapeutics , Arnings Per Share ,

Analyst Estimates: Here's What Brokers Think Of Halozyme Therapeutics, Inc. (NASDAQ:HALO) After Its Full-Year Report

Shareholders of Halozyme Therapeutics, Inc. ( NASDAQ:HALO ) will be pleased this week, given that the stock price is up. ....

Halozyme Therapeutic , Halozyme Therapeutics , Earnings Per Share , Price Target , Price Targets , Rowth Estimates , Revenue Growth ,

Q3 2024 Earnings Forecast for Halozyme Therapeutics, Inc. Issued By Zacks Research (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Research analysts at Zacks Research cut their Q3 2024 earnings per share (EPS) estimates for Halozyme Therapeutics in a research note issued on Thursday, February 1st. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings of $0.87 per share for the quarter, […] ....

United States , Michaelj Labarre , Hightower Advisors , Securities Exchange Commission , Goldman Sachs Group , Us Bancorp , Zacks Research , Financial Services Group Inc , Halozyme Therapeutics Inc , Morgan Stanley , Commonwealth Of Pennsylvania Public School Empls Retrmt , Halozyme Therapeutics , Free Report , Halozyme Therapeutic , Get Free Report , Tower Advisors , Services Group , Pennsylvania Public School Empls Retrmt , Exchange Commission , Halozyme Therapeutics Daily , Nasdaq Halo , Earnings Estimates ,